Clinigen Group (CLIGF) Stock Price, News & Analysis

Company Overview

Clinigen Group plc is a global specialty pharmaceutical and services company focused on improving patient access to critical therapies. The company sources, licenses and supplies unlicensed medicines and repurposed therapies for use where approved treatments do not exist or have been withdrawn. Clinigen’s commercial division partners with pharmaceutical innovators to acquire rights to niche, orphan or legacy products, ensuring continuity of supply and expanding patient access across targeted markets.

In addition to its commercial activities, Clinigen operates a comprehensive pharmaceutical services business. This segment offers clinical trial services, including packaging, labelling, distribution and global logistics, as well as analytical testing and stability services. The group also provides contract development and manufacturing services (CDMO), supporting pharma clients through formulation, scale-up and commercial manufacturing of sterile and non-sterile products.

Clinigen’s enhanced access programs enable patients and physicians to obtain unlicensed and investigational medicines via compassionate use, named-patient and expanded access schemes. These managed access initiatives are designed to address unmet medical needs, particularly in rare disease and oncology settings. By navigating complex regulatory pathways and managing supply chain logistics, Clinigen helps healthcare providers deliver therapies that would otherwise be unavailable.

Headquartered in Burton upon Trent in the United Kingdom, Clinigen serves healthcare markets across more than 100 countries worldwide. Since its establishment through strategic acquisitions and mergers in the early 2010s, the company has expanded its footprint in Europe, North America, Asia Pacific and emerging territories. Clinigen is led by an experienced executive team with backgrounds in pharmaceuticals, life-science services and global logistics, and its shares are traded on the London Stock Exchange with a secondary listing in the OTC market in the United States.

Key Stats

• Today's Range: $8.02 to $8.02
• 50-Day Range: $8.02 to $8.02
• 52-Week Range: $8.02 to $11.56
• Volume: N/A
• Average Volume: 8,620 shs
• Market Capitalization: $1.07 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CLIGF Stock Analysis - Frequently Asked Questions

How have CLIGF shares performed this year?

Clinigen Group's stock was trading at $8.0157 on January 1st, 2025. Since then, CLIGF shares have increased by 0.0% and is now trading at $8.0157.

How do I buy shares of Clinigen Group?

Shares of CLIGF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 10/15/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Private households
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CLIGF
• Previous Symbol: NASDAQ:CLIGF
• CIK: N/A
• Web: www.clinigengroup.com
• Phone: 44-12-8349-5010
• Fax: 01283 495011
• Employees: 1,069
• Year Founded: 2010

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $704.71 million
• Price / Sales: 1.51
• Cash Flow: $1.43 per share
• Price / Cash Flow: 5.60
• Book Value: $4.52 per share
• Price / Book: 1.77

Miscellaneous

• Outstanding Shares: 133,030,000
• Free Float: N/A
• Market Cap: $1.07 billion
• Optionable: Not Optionable
• Beta: 0.49